替罗非班和阿司匹林与氯吡格雷联合血塞通注射液治疗超溶栓时间窗急性进展性脑梗死患者的效果分析  

Effect Analysis of Tirofiban and Aspirin and Clopidogrel Combined with Xuesaitong Injection in the Treatment of Acute Progressive Cerebral Infarction after Thrombolytic Time Window

作　　者：刘永辉 LIU Yonghui(Department of Emergency,Ju County Traditional Chinese Medicine Hospital,Rizhao 276800,China)

机构地区：[1]山东省莒县中医医院急诊科,山东日照276800

出　　处：《中国伤残医学》2024年第24期82-85,90,共5页Chinese Journal of Trauma and Disability Medicine

摘　　要：目的:探讨替罗非班、氯吡格雷与阿司匹林联合血塞通注射液治疗超溶栓时间窗急性进展性脑梗死(APCI)患者的效果。方法:回顾性分析2022年1月—2024年1月莒县中医医院收治的76例超溶栓时间窗APCI患者资料,根据治疗方式不同将其分为对照组及研究组,各38例。两组均接受常规疗法,在此基础上,对照组采用替罗非班、氯吡格雷及阿司匹林治疗,研究组在对照组基础上采用血塞通注射液,均连续治疗14 d。对比两组的临床疗效、不良反应、凝血功能及神经功能。结果:研究组的治疗总有效率为94.74%,高于对照组的78.95%,差异有统计学意义(P<0.05)。治疗后,研究组的美国国立卫生研究院卒中量表评分为(13.11±1.01)分,低于对照组的(19.34±1.32)分,差异有统计学意义(P<0.05)。治疗后,研究组的凝血酶原时间、活化部分凝血活酶时间分别为(11.47±1.55)s、(27.11±2.68)s,均长于对照组的(10.74±1.36)s、(25.79±2.29)s,差异均有统计学意义(P<0.05)。研究组的不良反应发生率为13.16%,与对照组的7.89%比较,差异无统计学意义(P>0.05)。结论:对于超溶栓时间窗的APCI患者,采用替罗非班、氯吡格雷与阿司匹林联合血塞通注射液治疗展现出显著效果,不仅能优化凝血功能,加速神经功能的康复进程,还具备较高的安全性。Objective:To investigate the efficacy of Tirofiban and Clopidogrel and Aspirin in combined with Xuesaitong Injection the treatment of patients with acute progressive cerebral infarction(APCI)after thrombolytic time window.Methods:Data of 76 APCI patients after thrombolysis time window treated in Ju County Traditional Chinese Medicine Hospital from January 2022 to January 2024 were retrospectively analyzed.According to different treatment methods,they were divided into a control group and a study group,with 38 cases in each group.Both groups received conventional therapy.On this basis,the control group was treated with Tirofiban,Clopidogrel and Aspirin,and the study group was treated with was used Xuesaitong Injection on the basis of control group.Both groups were treated continuously for 14 days.The clinical efficacy,adverse reactions,coagulation function and nerve function of the two groups were compared.Results:The total effective rate of the study group was 94.74%,which was higher than 78.95%of the control group,the difference was statistically significant(P<0.05).After treatment,the National Institute of Health stroke scale of the study group was(13.11±1.01)points,which was lower than(19.34±1.32)points of the control group,and the difference was statistically significant(P<0.05).After treatment,the prothrombin time and activated partial thromboplastin time of the study group were(11.47±1.55)s and(27.11±2.68)s,respectively,which were longer than(10.74±1.36)s and(25.79±2.29)s of the control group,and the differences were statistically significant(P<0.05).The incidence of adverse reactions in the study group was 13.16%,compared with 7.89%in the control group,the difference was not statistically significant(P>0.05).Conclusion:For APCI patients after thrombolysis time window,Tirofiban,Clopidogrel and Aspirin combined with Xuesaitong Injection can show significant effects,which can not only optimize the coagulation function,accelerate the rehabilitation process of neurological function,but also have a high sa

关 键 词：急性进展性脑梗死 替罗非班 氯吡格雷 阿司匹林 神经功能 血塞通注射液 

分 类 号：R743.33[医药卫生—神经病学与精神病学]